A06-Clinical Oncology and Liquid Biopsy
Oncology / IBS-A06 / Consolidated
It is an active research group with stable connections with groups in the environment, at the regional and national level. Its intention is to link clinical and basic knowledge in a useful orientation for patients and for the evaluation of health services.
Research lines
- Circulating and diverse tumor cells
- Diet, physical exercise and cancer
- Evaluation of results in Cancer
- Response Modification by Mesenchymal Cells
- Single and fractional dose radiosurgery
- Radiotherapy with modified regimens (breast, lung, and others)
- Variability in Oncology Practice (Radiation Therapy)
Research networks
- CA17118 - Identifying Biomarkers Through Translational Research for Prevention and Stratification of Colorectal Cancer
- CA21116 - Identification of biological markers for prevention and translational medicine in pancreatic cancer (TRANSPAN)
DIEGO DE MIGUEL PEREZ
ABEL GARCIA DIAZ
VALERIA CECILIA DENNINGHOFF
ROSARIO CHING LOPEZ
Manuel Luis Blanco Villar
MARIA DEL CARMEN GARRIDO NAVAS
JOSE ANTONIO LORENTE ACOSTA
IGNACIO PUCHE SANZ
ROSARIO GUERRERO ROOF
MARIA JOSE SERRANO FERNANDEZ
ISABEL TOVAR MARTIN
MERCEDES ZURITA HERRERA
JOSE EXPOSITO HERNANDEZ
Title: IMMOBILIZATION CAPTURE OF EVS BY SPECIFIC BINDING OF A PEPTIDE TO ITS RECEPTOR T
Code: P202330039
Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family
CANCER COMMUNICATIONS, 2024;
FI: 20,1; D1
Spatially Preserved Multi-Region Transcriptomics Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
CLINICAL CANCER RESEARCH, 2024;
FI: 10,4; D1
Analyzing diagnosis and treatment wait time for lung cancer patients: key insight from a provincial registry study
Lung Cancer, 2024;
FI: 4,5; Q1
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024;
FI: 5,5; Q1
Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort
EUROPEAN UROLOGY OPEN SCIENCE, 2024;
FI: 3,2; Q1
Microfluidic systems in extracellular vesicles single analysis. A systematic review
TRAC TRENDS IN ANALYTICAL CHEMISTRY, 2023;
FI: 13,100; D1
Microfluidic amperometric immunosensor based on porous nanomaterial towards claudin7 determination for colorectal cancer diagnosis
TALANTA, 2023;
FI: 6,1; D1
Associations of accumulated persistent organic pollutants in breast adipose tissue with the evolution of breast cancer after surgery
SCIENCE OF THE TOTAL ENVIRONMENT, 2023;
FI: 9,8; D1
Antifibrotic Effects of Extracellular Vesicles From Umbilical Cord-Mesenchymal Stem Cells on Lung Myofibroblast Cells. Arch Bronconeumol
ARCHIVES DE BRONCONEUMOLOGIA, 2023;
FI: 8; Q1
microRNAs signature in relapse metastasis and de novo metastasis of breast cancer. A systematic review
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023;
FI: 6,2; Q1
Development of a new dual electrochemical immunosensor for a rapid and sensitive detection of enrofloxacin in meat samples
FOOD CHEMISTRY, 2022;
FI: 9,231; D1
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior.
THERANOSTICS, 2022;
FI: 11,6; D1
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022;
FI: 12,658; D1
Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer.
SCIENCE OF THE TOTAL ENVIRONMENT, 2022;
FI: 10,753; D1
A Novel, Quick, and Reliable Smartphone-Based Method for Serum PSA Quantification: Original Design of a Portable Microfluidic Immunosensor-Based System
CANCER, 2022;
FI: 6,575; Q1
Adipose Tissue Redox Microenvironment as a Potential Link between Persistent Organic Pollutants and the 16-Year Incidence of Non-hormone-Dependent Cancer.
ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2021;
FI: 9,028; D1
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
ANTIOXIDANTS, 2021;
FI: 6,313; D1
Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study
ARCHIVES DE BRONCONEUMOLOGIA, 2021;
FI: 4,872; Q2
Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021;
FI: 3,355; Q2
Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1
ONCOLOGICAL ACT, 2021;
FI: 4,089; Q3
COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population
THORAX, 2020;
FI: 10,844; D1
Evaluation of Changes in Control Status in COPD An Opportunity for Early Intervention
CHEST, 2020;
FI: 8,308; D1
Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020;
FI: 4,658; Q1
Clinical Control in COPD: A New Therapeutic Objective?
ARCHIVES DE BRONCONEUMOLOGIA, 2020;
FI: 4,957; Q1
A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020;
FI: 2,772; Q2
Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
CANCER, 2019;
FI: 6,162; Q1
Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents
CELLS, 2019;
FI: 5,656; Q1
Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
BREAST CANCER RESEARCH, 2019;
FI: 5,676; Q1
Liquid biopsy beyond cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019;
FI: 5,012; Q1
mRNA expression patterns in human myocardial tissue, pericardial fluid and blood, and their contribution to the diagnosis of cause of death
FORENSIC SCIENCE INTERNATIONAL, 2019;
FI: 1,99; Q1
Genetic markers a landscape in prostate cancer
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2018;
FI: 5,205; D1
Thyroid Cancer Epidemiology in South Spain: a population-based time trend study
ENDOCRINE, 2018;
FI: 3,179; Q2
A comprehensive study of circulating tumor cells at the moment of prostate cancer diagnosis: biological and clinical implications of EGFR, AR and SNPs
ONCOTARGET, 2017;
FI: 5,168; Q1
Role of radiosurgery in the management of glomus tumors
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016;
FI: 2,76; D1
Associations of persistent organic pollutants in serum and adipose tissue with breast cancer prognostic markers.
SCIENCE OF THE TOTAL ENVIRONMENT, 2016;
FI: 3,976; Q1
Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985-2012: a population-based study
CLINICAL & TRANSLATIONAL ONCOLOGY, 2016;
FI: 2,075; Q3
Serum and adipose tissue as matrices for assessment of exposure to persistent organic pollutants in breast cancer patients.
ENVIRONMENTAL RESEARCH, 2015;
FI: 4,373; D1
Risk of female breast cancer and serum concentrations of organochlorine pesticides and polychlorinated biphenyls: A case-control study in Tunisia
SCIENCE OF THE TOTAL ENVIRONMENT, 2015;
FI: 4,099; D1
F-18-Fluorocholine PET / CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015;
FI: 5,383; D1
Historical exposure to persistent organic pollutants and risk of incident hypertension
ENVIRONMENTAL RESEARCH, 2015;
FI: 4,373; D1
Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain
RADIATION ONCOLOGY, 2015;
FI: 2,546; Q2
IDENTIFICATION OF DETERMINANTS OF RESPONSE TO CHEMITRAPY/IMMUNOTHERAPY IN PATIENTS WITH SMALL LUNG CANCER
Funder: MUTUA MADRILEÑA FOUNDATION
File number: FMM-AP183262023
Execution time: 06/10/2023 - 05/10/2025
IP: MARIA JOSE SERRANO FERNANDEZ
IMNUNEXT
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: DTS23 / 00030
Execution time: 01/01/2024 - 31/12/2025
Subcontracting between UNIGE and FIBAO for the study of IL-38 charge in EVs Degree of contribution
Funder: UNIVERSITY OF GENEVA
File number: SERVICE CONTRACT
Running time: 2022 - 2023
Subsidies for the hiring of research personnel who hold the title of doctor or doctor in the field of health sciences and technologies (Project Identification of protein markers in extracellular vesicles (EVs) for the early diagnosis of lung cancer or pulmonary fibrosis Validation in patients with COPD or who have had COVID-19)
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: RH-0074-2020
Execution time: 01/01/2021 - 12/12/2023
Proteomic Study of Extracellular Vesicles (EVs) for the diagnosis and monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD)
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI22 / 01275
Execution time: 01/01/2023 - 31/12/2025
Role of platelets in the induction and potentiation of malignant features in lung tumor disease
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI21 / 00786
Execution time: 01/01/2022 - 31/12/2024
IP: MARIA JOSE SERRANO FERNANDEZ
Integration of clinical information; digital imaging and genomics: towards the Optimization of Precision Oncology – INGENIO
Funder: Carlos III Health Institute - PRTR
File number: PMP21/00137
Execution time: 01/01/2022 - 31/12/2022
IP: MARIA JOSE SERRANO FERNANDEZ
APPROACH TO ORAL HEALTH AND QUALITY OF LIFE IN SURVIVORS OF HEAD AND NECK CANCER USING PHOTOBIOMODULATION THERAPY COMPLEMENTED WITH AN M-HEALTH SYSTEM. L3AXER STUDIO.
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PI-0187-2021
Execution time: 09/12/2021 - 08/12/2024
PI: ISABEL TOVAR MARTIN
Liquid biopsy applied to the analysis of the evolution of chronic obstructive pulmonary disease and its association with lung cancer. (Colorado Project)
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PIP-0192-2020
Execution time: 21/12/2020 - 20/12/2023
PI: BERNARDINO ALCAZAR NAVARRETE
PI-0439-2014 - Study of the Variability and Adequacy of the Local and Adjuvant Treatment of Breast Cancer, Sarcomas and Primary Brain Tumors, in Public Hospitals of Andalusia (Study Vara-2014)
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
File number: PI-0439-2014
Execution time: 01/08/2015 - 31/07/2017
PI: ISABEL TOVAR MARTIN
ESR-17-12705 - MOLECULAR AND PHENOTYPIC PROFILES IN CIRCULATING TUMOR CELLS FROM OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS: ASSOCIATION WITH RELAPSE AND TREATMENT RESPONSE
Funder: ASTRAZENECA AB
File number: ESR-17-12705
Execution time: 01/01/2018 - 31/12/2018
IP: MARIA JOSE SERRANO FERNANDEZ
Translational Study on the Combined Use of Mesenchymal Stem Cells and Radiotherapy in the Treatment of Rectal Cancer
Funder: COUNCIL OF HEALTH
File number: PC-0252-2017
Execution time: 01/01/2018 - 31/12/2020
PI: ISABEL TOVAR MARTIN
Molecular and functional analysis of AR variants (AR-V7 and AR-V9) in platelets from patients with prostate cancer: prognostic and predictive markers of response to treatment.
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI17 / 00989
Execution time: 01/01/2018 - 31/12/2020
IP: MARIA JOSE SERRANO FERNANDEZ
Identifying Biomarkers Through Translational Research for Prevention and Stratification of Colorectal Cancer
Funder: EUROPEAN COMMISSION
File number: COST2017-CA17118
Execution time: 01/10/2018 - 30/09/2022
IP: MARIA JOSE SERRANO FERNANDEZ
Decision for or against Anti-PD-1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma
Funder: MFAR CLINICAL RESEARCH SL
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 10/12/24 - 30/12/25
PI: JAVIER VALDIVIA BAUTISTA
A randomized, controlled phase III study of IMC-F106C plus nivolumab versus nivolumab in HLA A*02:01-positive subjects with previously untreated advanced melanoma (PRISM-MEL-301)
Funder: IMMUNOCORE LIMITED
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 04/09/2024 - 15/12/2026
PI: JAVIER VALDIVIA BAUTISTA
Perioperative phase II and phase III trial of fianlimab and cemiplimab compared with an anti-PD1 alone in patients with resectable stage III and IV melanoma.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 11/11/2024 - 24/10/2030
PI: JAVIER VALDIVIA BAUTISTA
Perioperative phase II trial of fianlimab and cemiplimab in combination with chemotherapy versus cemiplimab in combination with chemotherapy in patients with resectable early-stage NSCLC (stages II to IIIB [N2]).
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 26/11/2024 - 03/06/2029
PI: JAVIER VALDIVIA BAUTISTA
THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+).
Funder: MON CLINIC BARCELONA PRIVATE FOUNDATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/11/2023 - 30/09/2025
PI: BERNARDINO ALCAZAR NAVARRETE
Phase IIb clinical study evaluating the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 alone, or Cetrelimab alone in participants with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calm
Funder: JANSSEN-CILAG, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/03/2023 - 30/03/2027
IP: IGNACIO PUCHE SANZ
A phase 3, randomized, multicenter study to evaluate the efficacy of TAR-200 in combination with cetrelimab compared with concomitant chemoradiotherapy in participants with non-retinal muscle-invasive bladder urothelial carcinoma (MIBC)
Funder: JANSSEN-CILAG, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 22/03/2023 - 20/10/2028
IP: IGNACIO PUCHE SANZ
Randomized, double-blind, placebo-controlled, parallel-group, multicenter, Phase IIa trial to evaluate the efficacy and safety of AZD4831, over 12-24 weeks, in moderate to severe chronic obstructive pulmonary disease (COPD) (CRESCENDO)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 25/11/2022 - 31/07/2024
PI: BERNARDINO ALCAZAR NAVARRETE
“Multicenter, randomized, double-blind, parallel-group, placebo-controlled study of mepolizumab 100 mg SC as adjunctive treatment in participants with COPD, experiencing frequent exacerbations and characterized by eosinophil levels
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/07/2022 - 31/07/2024
PI: BERNARDINO ALCAZAR NAVARRETE
Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Funder: GENENTECH INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 18/03/2022 - 30/08/2024
PI: BERNARDINO ALCAZAR NAVARRETE
Phase 2a, multicenter, parallel group, placebo-controlled, double-blind, randomized study to investigate the efficacy and safety of tezepelumab in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) (COURSE)
Funder: ASTRAZENECA AB
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 17/06/2022 - 30/03/2024
PI: BERNARDINO ALCAZAR NAVARRETE
Phase IIa, double-blind, randomized, parallel, placebo-controlled trial to investigate the effect of PBF-680 in conjunction with usual medication in subjects with moderate to severe COPD.
Financier: PALOBIOFARMA SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 20/06/2022 - 30/06/2023
PI: BERNARDINO ALCAZAR NAVARRETE
Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety of RO7486967 in Patients With Chronic Obstructive Pulmonary Disease
Financier: F. HOFFMANN-LA ROCHE LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 20/01/2022 - 30/12/2022
PI: BERNARDINO ALCAZAR NAVARRETE
Phase II, multicenter, randomized, parallel-group study to evaluate the safety, tolerability, and pharmacokinetics of a second-generation VIR-7831 in non-hospitalized participants with mild coronavirus disease 2019 (COVID-19).
Funder: VIR BIOTECHNOLOGY INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/06/2021 - 28/02/2022
PI: BERNARDINO ALCAZAR NAVARRETE
Historical values vs. Current blood eosinophils in patients with severe uncontrolled asthma: predictive ability of future risks. ENEAS II study.
Funder: SPANISH LUNG FOUNDATION - RESPIRA
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 17/09/2020 - 30/04/2021
PI: BERNARDINO ALCAZAR NAVARRETE
Multicenter, Randomized, Double-Blind, Parallel Group Trial to Evaluate Efficacy and Safety of PT009 Compared to PT005 in COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 22/11/2016 - 30/08/2018
PI: BERNARDINO ALCAZAR NAVARRETE
